Angiotensin-II Receptor Antagonists: New Generation Antihypertensives - Bali, Alka
46,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

The renin-angiotensin-aldosterone system (RAAS) has a central role in the expression and modulation of cardiovascular diseases, particularly, hypertension. The development of non-peptide, orally active angiotensin II receptor antagonists is the most recent focus area in antihypertensive drug development. Angiotensin II receptor antagonists/blockers (ARBs) are recognized as one of the most effective means of lowering blood pressure in hypertensive patients as these overcome the limitations of other drug classes such as angiotensin converting enzyme (ACE) inhibitors, beta blockers or renin…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
The renin-angiotensin-aldosterone system (RAAS) has a central role in the expression and modulation of cardiovascular diseases, particularly, hypertension. The development of non-peptide, orally active angiotensin II receptor antagonists is the most recent focus area in antihypertensive drug development. Angiotensin II receptor antagonists/blockers (ARBs) are recognized as one of the most effective means of lowering blood pressure in hypertensive patients as these overcome the limitations of other drug classes such as angiotensin converting enzyme (ACE) inhibitors, beta blockers or renin inhibitors. ARBs offer cardiovascular and renal protection benefits independent of their effects on systemic blood pressure, which makes them valuable as first line antihypertensive agents, especially in high-risk patients. Due to these facts, recent years have seen a spurt in the introduction of newer agents structurally related to losartan, the prototypic agent of this class.
Autorenporträt
Alka Bali is an Associate Professor in Pharmaceutical Chemistry at University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India. She has been working in the area of synthetic medicinal chemistry with particular emphasis on development of novel angiotensin II antagonists, atypical antipsychotics and COX-2 inhibitors.